The Cirino Regenerative Technique

In 2024, I wrote a post on the subdermal scalp infusion of drugs by tattooing to induce hair growth. The process of skin microinfusion of medications (MMP®) was first outlined in 2013 by Brazilian dermatologist Dr. Samir Arbache. But Dr. Pablo Cirino (Brazil) started using the tattoo machine in his own way with his own protocol for the purposes of scalp hair growth. He originally called his process “combined regenerative technique” and published a paper on it in September 2025.

Cirino Regenerative Technique (CRT): Before and After Hair Growth.
Cirino Regenerative Technique (CRT): Before and after hair growth.

Cirino Regenerative Technique (aka Combined Regenerative Technique)

As of 2026, Dr. Cirino now calls his process the Cirino Regenerative Technique (CRTTM). He has made a number of modifications to the original version insofar as what drugs, peptides, growth factors and micronutrients to use.

The delivery mechanism via precision microinfusion technology using a tattooing machine type device remains the same. It creates thousands of microscopic channels across the scalp at a controlled depth. This allows the various hair growth customized medications to be delivered directly to the hair follicle at the dermal papilla level. This is superior in comparison to your typical topical gels, serums, liquids, creams and lotions. In addition, this method stimulates natural growth factors and regenerative processes. I think there is a microneedling type effect, but I am not sure.

CRT is now becoming especially popular in the hair loss world so I decided to write this post. Moreover, a number of renowned hair transplant surgeons are being trained to use CRT at their clinics (see the end of this post). Also check out Spex’s new interview with Dr. Cirino further below.

Cirino Regenerative Technique (CRT): Before and After Hair Regrowth.
Cirino Regenerative Technique (CRT): Before and after hair regrowth.

In a response to me in 2025, Dr. Cirino said that he delivers the below combination of topical drugs with a tattoo machine for transcutaneous delivery:

  • Arginine 200 µg. This is an amino acid.
  • Biotin (Vitamin B7) 50 µg.
  • Copper Sulfate 2 µg.
  • Chromium 0.2 µg.
  • Dexpanthenol 20 µg.
  • Riboflavin (Vitamin B2) 10 µg.
  • Vitamin B6 6 µg.

In addition, for males with androgenetic alopecia (AGA), he adds the following:

  • Minoxidil 0.5%.
  • Finasteride 0.05%.
  • Dutasteride 0.1%

For females with AGA (i.e., female pattern hair loss), he adds the following:

CRT Scalp Microinfusion of Drugs via Tattooing for Thinning Hair.
CRT scalp microinfusion of drugs via tattooing for thinning hair.

This week, Dr. Cirino told me that he now also uses some growth factors from PRP. Moreover, after studying the main hair growth pathways, he has also added some “home treatments” to patients to boost the results. I presume one can also use exosomes, even though he did not mention it.

He never prescribes oral finasteride or oral dutasteride, preferring to apply both topically via his scalp microinfusion via tattooing technique. He does prescribe oral minoxidil.

In a January 2026 article, Dr. Cirinho mentions that the combined regenerative technique:

“Integrates tattoo machine-assisted infusion of minoxidil sulfate, dutasteride, copper peptides, and platelet-rich plasma with concurrent oral minoxidil and topical finasteride.”

Combined Regenerative Technique Hair Growth. Before and After.
Combined regenerative technique for hair growth. Before and after.

All of this reminds me of the kitchen skin approach to tackling hair loss that we have discussed numerous times on this blog. Except that in this case, it is via a superior delivery mechanism of topical medications directly to the scalp. And from a doctor who has been experimenting with various regimens for a number of years.

On a related note, make sure to read my 2019 post on creating the ultimate hair loss drug cocktail. Most online vendors of topical finasteride these days also offer a mix of molecules in one serum.

Dr. Pablo Cirino Interview: Non-Surgical Hair Growth via CRT

Earlier this month, Dr. Pablo Cirino gave a lengthy interesting interview to Spencer (“Spex”) Stevenson that I have embedded below. Among the highlights:

  • His CRT method has led to 40% of his patients ultimately not needing a hair transplant.
  • The cost is just $500 at his Brazil clinic.
  • 1 million micro-perforations per treatment.
  • He is training many surgeons from around the world via his Tricho Surgery Academy.
  • Most people need one 30-minute treatment session each month for 6 months total. Thereafter, maintenance options are based on individual needs and preferences.
  • He recommends Chemistry Rx in the US for compounding unique hair loss drugs. I have talked about this company in the past too.

Cirino Regenerative Technique Training Sessions

In 2026, Dr. Cirino has started training many other doctors and hair transplant surgeons in regards to his CRT technique. Check out his Tricho Surgery Academy for more information as well as numerous photos and training session videos.

A number of globally renowned hair transplant surgeons are now proponents of this unique method of delivering multiple hair loss drugs to the scalp subcutaneously. Note that some of them are using existing scalp micropigmentation (SMP) devices to make the holes or incisions.

Videos

Other Drug Delivery Mechanisms to the Scalp

Over the years, I have discussed many different ways of delivering drugs directly to the scalp. Among these include:

Hopefully the CRT method turns out to be the best of these options, although it is still too early to tell.

A List of New Technology Hair Growth Cosmeceuticals Released in 2024, 2025 and 2026

During the past three years, a large number of unique and promising topical hair growth cosmeceuticals have entered the market. None of these have gone through all three phases of clinical trials, though one (KX-826) is currently in Phase 3 trials. All of these cosmeceuticals have some legitimate science behind their potential efficacy.

This rapid proliferation of new well researched cosmeceuticals that can be purchased online to fight hair loss is encouraging. Even if many of the beneficial claims (often in mice) turn out to be exaggerated. Hair loss sufferers are tired of lengthy clinical trials that ultimately lead to nowhere. So I am glad about this “shortcut” to market. Most importantly, we have thus far not heard of any major issues with side effects from any of these new hair loss products.

Note that the term “cosmeceutical” is a portmanteau of the words “cosmetic” and “pharmaceutical”. However, the FDA does not recognize it, and says that such a product has to be classified as: a (topical) drug, or a cosmetic, or both.

New Topical Hair Growth Cosmeceuticals

  1. CosmeRNA Hair Loss Cosmeceuticals
    CosmeRNA for hair loss.

    The product that started this recent trend was CosmeRNA, first released in May 2023 in Western Europe by Bioneer (South Korea). In 2024, it was released in the US on Amazon. CosmeRNA targets the androgen receptor via self-assembled micelle inhibitory RNA (SAMiRNA) nanoparticle-type siRNA. Prior to the product’s release, the scientists behind its development published a study in Nature in January 2022.

  2. Yuva Biosciences BosleyMD Revive+ for Hair Loss.
    Yuva Biosciences BosleyMD Revive+ Foam for Hair Loss.

    In February 2024, Bosley (US) and Yuva Biosciences (US) together released a new hair loss foam product that works by boosting mitochondria levels in scalp hair. It contains Yuva’s Y100™ small molecule that improves mitochondrial function, and is sold on Amazon.

    Moreover, in December 2024, Elevai Labs (US) and Yuva launched a new line of hair loss products (shampoo, conditioner and serum) that contain Elevai ‘s PREx Exosomes™ and Yuva’s Y100™. Also of note, Atticus Pharma (US) is working on a hair growth topical product that will deliver a mitochondrial-activating molecule using the company’s Z-pod sustained-release technology.

  3. Kintor Hair Loss Cosmeceutical
    Kintor Hair Loss Cosmeceutical.

    In June 2024, Kintor Pharmaceutical (China) released its much anticipated KX-826 (pyrilutamide) hair growth spray on Amazon. While the original version was at a strength of 0.5%, the company released a higher-strength version in 2025. This was followed by two additional versions, including a foam.

    KX-826 is an androgen receptor antagonist, and is currently in Phase 3 clinical trials in both China and the US. It is expected to get released in China in 2027. Meanwhile, for the time being, we have the option to buy the cosmecutical version of KX-826 from Amazon.

  4. In October 2025, a South Korea based company called AriBio received permission from the Ministry of Food and Drug Safety to market its TeloAct product as a hair loss cosmetic. This topical product activates telomerase enzymes, which supposedly helps prevent hair loss due to telomere shortening. Read more about this in my post on telomerase activation and hair growth.
  5. In November 2025, Mallia Therapeutics (Germany) released its 8T3 Essentials Hair Serum. This hair growth product is based on a molecule called MAL-838, which is derived from a soluble version of the CD83 protein (aka sCD83). Research has indicated that hair follicle formation and wound healing are improved in CD83-treated mice.
  6. Coegin Pharma (Sweden) released its Follicopeptide gel serum hair growth product in December 2025. This was followed by another one called VEXIENNE® Hair Active X™ in July 2026. This osteopontin-derived peptide product for hair growth has a decade of research behind it via Follicum (a company that was purchased by Coegin in 2022).
  7. CK Regeon (South Korea) released its PTD-DBM hair booster (brand name HAIRREGEON) in July 2026. In addition, the company also released a set of four topical products (including a shampoo) under the brand name HERIBON.
  8. A number of topical exosome products for hair growth were released in 2024 and 2025, with Calecim getting the most publicity. Some of them are only available at doctor or surgeon offices and often applied after scalp microneedling.

Other Potential Future Topical Hair Loss Cosmeceuticals

In July 2024, a study from the UK captured global media attention due to its viral finding that a naturally occurring sugar (2-deoxy-D-ribose — 2dDr) could reverse hair loss. The results were only in mice, and I doubt that anything significant will be seen in humans. Nevertheless, the scientists behind these findings plan to further research the potential of developing a topically delivered sugar gel product for human scalps. Meanwhile, a number of companies and entrepreneurs have already started selling cosmeceuticals based on 2dDr online.

OliX Pharmaceuticals (South Korea) is conducting Phase 2 clinical trials for its topical hair growth product OLX104C that targets the androgen receptor. In the meantime, in June 2025, they launched a functional hair loss cosmetic called U:BERNA. However, it is unclear if there is any link to OLX104C in terms of mechanism of action.

In October 2025, we heard about a new fatty acid serum from Taiwan that will likely be a cosmeceutical if and when released. The product will not need to go through any clinical trials since its fatty acid ingredients are already well established and safe.

Energenesis (Taiwan) is working on a topical AMP-activated protein kinase (AMPK) hair growth cosmetic product. It boosts the adenosine triphosphate (ATP) levels of human follicle dermal papilla cells. On a related note, Spain-based Ideeea Therapeutics is working on developing an injectable treatment consisting allogeneic mesenchymal stem cells (derived from adipose tissue) combined with ATP.

Topical androgen receptor inhibitor Breezula from Cosmo Pharmaceuticals (Ireland) is also currently in Phase 3 clinical trials. Unlike what Kintor did with its earlier mentioned androgen receptor antagonist, Cosmo does not plan to release any cosmeceutical version of Breezula in advance of official government approval for its main product.

Note that the much anticipated PP405 from Pelage Pharmceuticals is a topical hair loss product that will enter Phase 3 clinical trials in 2026. However, it does not seem like the company plans to release any cosmeceutical version in advance.

Hope Medicine’s HMI-115 prolactin blocker is delivered via injection, so it is not exactly a topical (lotion, cream, gel or spray). But I will still mention it here since it has completed Phase 2 trials and is also very eagerly awaited.